Xanodyne Pharmaceuticals announces new president, CEO

6/5/2009

NEWPORT, Ky. Xanodyne Pharmaceuticals, a specialty pharmaceutical company focused on women's health care and pain management, announced the appointment of Michael Valentino to president and CEO.

Valentino was previously president and CEO at Adams Labs. Before that, he was EVP and global head of consumer pharmaceuticals at Novartis.

Xanodyne develops such products as prenatal vitamins and pain relievers.

X
This ad will auto-close in 10 seconds